Kinetics of Influenza A Virus Infection in Humans

  • Prasith Baccam
    Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico 87545
  • Catherine Beauchemin
    Department of Physics, University of Alberta, Edmonton, Alberta, T6G 2J1, Canada
  • Catherine A. Macken
    Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico 87545
  • Frederick G. Hayden
    Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22908
  • Alan S. Perelson
    Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico 87545

書誌事項

公開日
2006-08
権利情報
  • https://journals.asm.org/non-commercial-tdm-license
DOI
  • 10.1128/jvi.01623-05
公開者
American Society for Microbiology

この論文をさがす

説明

<jats:title>ABSTRACT</jats:title><jats:p>Currently, little is known about the viral kinetics of influenza A during infection within an individual. We utilize a series of mathematical models of increasing complexity, which incorporate target cell limitation and the innate interferon response, to examine influenza A virus kinetics in the upper respiratory tracts of experimentally infected adults. The models were fit to data from an experimental H1N1 influenza A/Hong Kong/123/77 infection and suggest that it is important to include the eclipse phase of the viral life cycle in viral dynamic models. Doing so, we estimate that after a delay of ∼6 h, infected cells begin producing influenza virus and continue to do so for ∼5 h. The average lifetime of infected cells is ∼11 h, and the half-life of free infectious virus is ∼3 h. We calculated the basic reproductive number,<jats:italic>R</jats:italic><jats:sub>0</jats:sub>, which indicated that a single infected cell could produce ∼22 new productive infections. This suggests that antiviral treatments have a large hurdle to overcome in moderating symptoms and limiting infectiousness and that treatment has to be initiated as early as possible. For about 50% of patients, the curve of viral titer versus time has two peaks. This bimodal behavior can be explained by incorporating the antiviral effects of interferon into the model. Our model also compared well to an additional data set on viral titer after experimental infection and treatment with the neuraminidase inhibitor zanamivir, which suggests that such models may prove useful in estimating the efficacies of different antiviral therapies for influenza A infection.</jats:p>

収録刊行物

  • Journal of Virology

    Journal of Virology 80 (15), 7590-7599, 2006-08

    American Society for Microbiology

被引用文献 (14)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ